Igata Yu, Kudo Masashi, Kojima Motohiro, Kami Shota, Aoki Keishiro, Satake Tomoyuki, Kobayashi Tatsushi, Sugimoto Motokazu, Kobayashi Shin, Konishi Masaru, Gotohda Naoto
Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.
World J Clin Cases. 2024 Dec 6;12(34):6721-6727. doi: 10.12998/wjcc.v12.i34.6721.
The combination of immune checkpoint inhibitors and chemotherapy has shown promising results for the treatment of advanced biliary tract cancer (BTC). Based on the results of the TOPAZ-1 trial, a gemcitabine and cisplatin plus durvalumab (GCD) regimen was recently approved as first-line therapy for patients with advanced BTC. However, post-GCD conversion surgery has not been previously studied. Herein, we describe a case of advanced intrahepatic cholangiocarcinoma (ICC) successfully treated with radical surgery after GCD.
A 65-year-old female diagnosed with advanced ICC with periductal infiltration into the hepatic hilum underwent eight cycles of GCD, followed by durvalumab maintenance treatment, with mild adverse events. Partial response was obtained. Subsequently, a conversion surgery with extended left hepatectomy and bile duct resection was performed. The resection margins were negative, and the pathological diagnosis was compatible with small duct type ICC. The patient remained disease-free for 8 months without adjuvant chemotherapy.
We describe the case of a patient who received successful conversion surgery after GCD treatment for advanced ICC.
免疫检查点抑制剂与化疗联合应用在晚期胆管癌（BTC）治疗中已显示出有前景的结果。基于TOPAZ - 1试验的结果，吉西他滨和顺铂加度伐利尤单抗（GCD）方案最近被批准作为晚期BTC患者的一线治疗方案。然而，此前尚未对GCD治疗后转换手术进行研究。在此，我们描述一例晚期肝内胆管癌（ICC）患者在接受GCD治疗后成功接受根治性手术的病例。
一名65岁女性被诊断为晚期ICC，肝门部胆管周围浸润，接受了8个周期的GCD治疗，随后进行度伐利尤单抗维持治疗，不良事件轻微。获得了部分缓解。随后，进行了扩大左肝切除和胆管切除的转换手术。切缘阴性，病理诊断符合小胆管型ICC。该患者未接受辅助化疗，无病生存8个月。
我们描述了一例晚期ICC患者在接受GCD治疗后成功进行转换手术的病例。
